Gynaecological Cancer

Clinical trials for patients with cancer of the female reproductive system. This includes endometrial, cervix, ovaries and vagina.

If you would like to be considered for a clinical trial you will require a referral from your current treating team. Visit the Joining a Clinical Trial page for referral information. 

For more information on clinical trials, get in contact with our cancer clinical trials enquiry coordinator.

Clinical Trials Enquiry Coordinator

Business hours, Mon to Friday between 9am - 2pm
Email [email protected]
Phone (03) 8559 7456

Open and Recruiting Clinical Trials

A clinical trial to test the effectiveness of Adavosertib targeting in women with high grade serous ovarian cancer that are overexpressing Cyclin 1 (CCNE1)

Cancer type

Ovarian Cancer overexpressing Cyclin 1 (CCNE1)

Status

Open and recruiting

Phase

Two: A phase two clinical trial follows a phase one, in a large group of patients with selected cancer types. The aim of a phase two is to find out if the new treatment is effective in these cancer types.

Brief summary

The IGNITE Clinical trial is designed to see if giving regular Adavosertib is a safe and effective option for women with high grade ovarian cancer that has come back. This study is enrolling women with ovarian cancer that overexpression of Cyclin 1 (CCNE1). All women will receive Adavosertib orally.

Who can participate

Women who:

  • Have high grade serous ovarian cancer that has come back
  • Have high grade serous ovarian cancer overexpressing Cyclin 1 (CCNE1)

Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial. 

A clinical trial to test the safety and effectiveness of Bevacizumab, Atezolizumab and Cobimetinib in women with platinum resistant high grade serous Ovarian cancer that has come back

Cancer type

High grade serous ovarian cancer

Status

Open and recruiting

Phase

Two: A phase two clinical trial follows a phase one, in a large group of patients with selected cancer types. The aim of a phase two is to find out if the new treatment is effective in these cancer types.

Brief summary

A clinical trial to test if giving Bevacizumab, Atezolizumab and Cobimetinib together is safe and effective in women with platinum resistant high grade serous ovarian cancer that has come back. The clinical trial will test if the combined treatment can shrink the cancer or stop the cancer from growing.

Who can participate

Women who:

  • Have High grade serous ovarian cancer
  • Have Platinum resistant or refractory recurrent disease

Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial. 

A clinical trial of Pamiparib for women with fusion positive, Reversion negative High Grade Serous ovarian Cancer or Carcinosarcoma who have progressed on previous treatment

Cancer type

High Grade Serous Ovarian Cancer

Status

Open and recruiting

Phase

Two: A phase two clinical trial follows a phase one, in a large group of patients with selected cancer types. The aim of a phase two is to find out if the new treatment is effective in these cancer types.

Brief summary

The clinical trial will test the effectiveness of Pamiparib in women with Germline or Somatic BRCA1/2 High Grade Serous Ovarian Cancer or Carcinosarcoma that is positive for the ABCB1 fusion and negative for the BRCA1/2 Reversion.

Who can participate

Patients who:

  • Have high grade serous ovarian cancer
  • Have Carcinosarcoma of the ovary (including primary peritoneal cancers and Fallopian tube.

Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial. 

A clinical trial to test the effectiveness of Olaparib and Cediranib or Olaparib alone in patients with platinum-sensitive ovarian cancer that has come back following a response to platinum-based chemotherapy

Cancer type

Cancer of the ovary, fallopian tube or peritoneum

Status

Open and recruiting

Phase

Three: A phase three clinical trial follows a phase two, in a larger group of patients with specific cancer types. The aim of a phase three is to compare the new treatment to what is available for that cancer type.

Brief summary

A clinical trial to test if Olaparib and Cediranib given together is better than Olaparib given alone following a response to chemotherapy for women with relapsed platinum sensitive ovarian, fallopian tube or peritoneal cancer.

Who can participate
  1. Women with a diagnosis of cancer that:
  • Is high grade serous or endometrioid cancer of the ovary, fallopian tube or peritoneum,
  • Has progressed  more than 6 months after chemotherapy
  • Now requires more chemotherapy

Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.

A clinical trial to test if giving low dose of Cyclophosphamide with Olaparib to before starting Olaparib with Durvalumab is better than Olaparib given alone followed by Olaparib and Durvalumab in patients with asymptomatic platinum-sensitive recurrent ovarian, fallopian tube or primary peritoneal cancers with genetic changes that cause the cancer to grow

Cancer type

Recurrent ovarian, fallopian tube or primary peritoneal cancers

Status

Open and recruiting

Phase

Two: A phase two clinical trial follows a phase one, in a large group of patients with selected cancer types. The aim of a phase two is to find out if the new treatment is effective in these cancer types.

Brief summary

A clinical trial to test if giving low dose of Cyclophosphamide with Olaparib to prepare the immune system before starting Olaparib with Durvalumab will be better than Olaparib given alone followed by Olaparib and Durvalumab and will delay patients’ cancer becoming worse.

Who can participate
  • Have High-grade serous carcinoma of the ovary, fallopian tube or primary peritoneum
  • Have BRCA germline mutation and/or platinum sensitivity
  • Have First asymptomatic CA125 progression

Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.

A clinical trial to test the effectiveness of acetylsalicylic acid in preventing ovarian cancer in women with a BRCA ½ mutation

Cancer type

Women with a known BRCA 1/2 mutation

Status

Open and recruiting

Phase

Two: A phase two clinical trial follows a phase one, in a large group of patients with selected cancer types. The aim of a phase two is to find out if the new treatment is effective in these cancer types.

Brief summary

A clinical trial to test whether giving women with a known BRCA ½ mutation acetylsalicylic acid will reduce their risk of getting ovarian cancer.

Patients will be given one of the following:

  • Acetylsalicylic acid for a minimum of 6 months to a maximum of two years followed by risk-reducing surgery
  • Placebo for a minimum of 6 months to a maximum of two years followed by risk-reducing surgery
Who can participate

Women who:

  • Have a known BRCA1/2 mutation
  • Are scheduled to undergo risk reducing surgery
  • Are able to swallow medication by mouth

Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.